<DOC>
	<DOCNO>NCT02240459</DOCNO>
	<brief_summary>The purpose study assess effect fesoterodine 4mg 8mg dos versus placebo oxybutynin 5mg bid versus placebo cognitive ability older people overactive bladder mild cognitive impairment .</brief_summary>
	<brief_title>A Study Fesoterodine Oxybutynin Cognitive Function Mild Cognitive Impairment</brief_title>
	<detailed_description>This randomize placebo control , blind four way cross trial effect medication use treat overactive bladder cognition old men woman mild cognitive impairment . Each treatment phase week , week washout period start next treatment . Cognitive test way validate computer assist battery test</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>1 . The subject either male female â‰¥ 75 year age . 2 . The subject OAB determine ICS criterion 3 . The subject mild cognitive impairment determine NIA criterion 4 . The subject competent give inform consent perform task associate study 5 . The subject body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive . 6 . Written inform consent obtain . 7 . The subject available complete study . 8 . At train visit ( visit 2 ) : subject perform minimum level least one occasion individual task measure cognitive function test training . 1 . The subject OAB . 2 . The subject either dementia moderate severe cognitive impairment screening . 3 . The subject probable clinical depression determine Geriatric Depression Scale ( GDS ) short form &gt; 5 screening . 4 . Subjects take cognitive enhancer ( cholinesterase inhibitor memantine ) . 5 . The subject history allergy study drug ( ) , component dosage form allergy , , opinion Investigator , contraindicate participation . 6 . The subject clinically significant abnormal heart rate blood pressure measurement , screen visit , , opinion Investigator , prevent safe participation study . ( dBP &lt; 60mmHg &gt; 90mmHg , sBP &lt; 95mmHg &gt; 160mmHg HR &lt; 40bpm &gt; 100bpm ) . 7 . Subjects know history urinary retention , severe gastrointestinal obstruction ( include paralytic ileus intestinal atony ) severe gastrointestinal condition ( include toxic megacolon ulcerative colitis ) , myasthenia gravis , uncontrolled narrow angle glaucoma shallow interior chamber subject deem risk condition . 8 . Subjects undergoing haemodialysis severe renal impairment . 9 . Subjects severe hepatic impairment , define ChildPugh grade IV . 10 . Subjects take potent CYP 3A4 inhibitor would , normal circumstance , require adjustment dose test drug . 11 . Subject take prescribed medication within 14 day prior first study day overthecounter medicine ( include vitamin herbal remedy ) within 48 hour prior first study day , opinion Investigator , interfere study procedure compromise safety . 12 . Subject average weekly alcohol intake great 21 unit ( male ) 14 unit ( female ) within 90 day prior study . 1 unit 270cc beer , 40cc spirit 125cc wine . 13 . History smoke 10 cigarette ( equivalent amount tobacco ) per day within 90 day prior study . 14 . Subject participate clinical study within last 90 day . 15 . Any clinically significant abnormality follow Investigator review pre study physical examination . 16 . Any clinical condition , , opinion Investigator , would allow safe completion study . 17 . Any subject , opinion investigator , may find difficult adhere provision treatment observation specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>crossover study</keyword>
	<keyword>placebo control</keyword>
	<keyword>double blind</keyword>
	<keyword>overactive bladder</keyword>
</DOC>